Spanish pharma deal & funding model fillip for medtech?
This article was originally published in Clinica
The Spanish pharmaceutical industry has reached an agreement with the government, said to be worth up to Pta442.5 billion ($2.5 billion) to the healthcare system in savings on medicine prices and investments in healthcare research in 2002-04. The deal will go some way to appeasing the devices industry, which has long borne the brunt of financial shortfalls at the expense of pharma spending.
You may also be interested in...
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.